[KongchangAI]
Unverified50% confidenceFactExact time

Ipilimumab (an anti-CTLA-4 antibody), the first immune checkpoint inhibitor approved by the FDA in 2011, achieved an initial breakthrough in melanoma.

1
Sources
50%
Confidence
Long-term
Relevance
9/7/2026
First Seen

Sources

Moderna's Personalized Cancer Vaccine Succeeds in Phase 3 Trial, Stock Surges 110%

Related Entities

ipilimumabproductFDAcompany黑色素瘤concept

Related Claims

UnverifiedmRNA-4157/V940 is used in combination with Merck's immune checkpoint inhibitor Keytruda (pembrolizumab).54% similar

Cite This Claim

Stable URI
https://kongchang.com/claim/873258
API
curl https://kongchang.com/api/v1/knowledge/claims/873258
MCP
get_claim(id=873258)